Pfizer's experimental lung cancer drug fails to extend survival in late-stage trial

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study

ANGELA WEISS / Getty Images

Pfizer $PFE announced Monday that its experimental lung cancer drug sigvotatug vedotin failed to extend patient survival in a late-stage clinical trial, falling short of the study's primary endpoint.

Pfizer said the Phase 3 SigVie-002 trial found that patients with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer who had already undergone one or more prior treatments lived no significantly longer on the drug than those who received docetaxel, a standard chemotherapy. The study........

© Quartz